172 related articles for article (PubMed ID: 36916414)
1. Clinical application of the anti-human telomerase reverse transcriptase (hTERT) antibody (SCD-A7) immunocytochemistry in liquid-based urine cytology: A prospective, single institute study.
Moon JH; Nikas IP; Moon KC; Kim B; Ryu HS
Cancer Med; 2023 May; 12(9):10363-10370. PubMed ID: 36916414
[TBL] [Abstract][Full Text] [Related]
2. An institutional experience evaluating hTERT immunostaining in 100 consecutive ThinPrep urine specimens.
Xing J; Han M; Monaco SE; Dhir R; Roy S; Pantanowitz L
J Am Soc Cytopathol; 2021; 10(1):88-93. PubMed ID: 32354607
[TBL] [Abstract][Full Text] [Related]
3. Comparison of human telomerase reverse transcriptase messenger RNA and telomerase activity as urine markers for diagnosis of bladder carcinoma.
Bialkowska-Hobrzanska H; Bowles L; Bukala B; Joseph MG; Fletcher R; Razvi H
Mol Diagn; 2000 Dec; 5(4):267-77. PubMed ID: 11172490
[TBL] [Abstract][Full Text] [Related]
4. [Value of CK20 immunocytochemistry as an adjuvant to urine liquid-based cytology in detection of urothelial carcinoma].
Li M; Li HX; Guo HQ; Zhao H; Zhao LL; Ma JH; Li CL; Cao J; Pan QJ
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):669-73. PubMed ID: 23159079
[TBL] [Abstract][Full Text] [Related]
5. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
6. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker.
Melissourgos N; Kastrinakis NG; Davilas I; Foukas P; Farmakis A; Lykourinas M
Urology; 2003 Aug; 62(2):362-7. PubMed ID: 12893365
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Sienna Cancer Diagnostics hTERT Antibody on 500 Consecutive Urinary Tract Specimens.
Allison DB; Sharma R; Cowan ML; VandenBussche CJ
Acta Cytol; 2018; 62(4):302-310. PubMed ID: 29874657
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
[TBL] [Abstract][Full Text] [Related]
9. Quest to develop a standard screening method for urothelial carcinoma using liquid-based cytology (The Paris System) and CK20.
Jain K; Datta C; Sengupta M; Pal DK; Chatterjee U
Indian J Pathol Microbiol; 2023; 66(4):720-726. PubMed ID: 38084522
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of urinary human telomerase reverse transcriptase mRNA and scatter factor protein as urine markers for diagnosis of bladder cancer.
Eissa S; Motawi T; Badr S; Zaghlool A; Maher A
Clin Lab; 2013; 59(3-4):317-23. PubMed ID: 23724620
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine.
Brisuda A; Háček J; Čechová M; Škapa P; Babjuk M
Cytopathology; 2019 Sep; 30(5):510-518. PubMed ID: 30943322
[TBL] [Abstract][Full Text] [Related]
12. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer.
Weikert S; Krause H; Wolff I; Christoph F; Schrader M; Emrich T; Miller K; Müller M
Int J Cancer; 2005 Nov; 117(2):274-80. PubMed ID: 15900578
[TBL] [Abstract][Full Text] [Related]
13. Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.
Dugas SG; Müller DC; Le Magnen C; Federer-Gsponer J; Seifert HH; Ruiz C; Savic Prince S; Vlajnic T; Zellweger T; Mertz KD; Bacon JVW; Wyatt AW; Rentsch CA; Bubendorf L
Cancer Cytopathol; 2019 Sep; 127(9):578-585. PubMed ID: 31386310
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical staining for p53 and Ki-67 helps to characterise urothelial cells in urine cytology.
Courtade-Saïdi M; Aziza J; d'Aure D; Bérard E; Evrard S; Basset C; Lacoste-Collin L
Cytopathology; 2016 Dec; 27(6):456-464. PubMed ID: 27873391
[TBL] [Abstract][Full Text] [Related]
15. Urine cytology findings in patients with biopsy-confirmed urothelial carcinoma in situ with plasmacytoid features.
Nichols MM; Reynolds JP; McKenney JK; Nicolas MM; McIntire PJ; Policarpio-Nicolas MLC
Cancer Cytopathol; 2021 Oct; 129(10):798-804. PubMed ID: 33900681
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of hTERT in urothelial lesions: a potential adjunct to urine cytology.
Khalbuss W; Goodison S
Cytojournal; 2006 Aug; 3():18. PubMed ID: 16901344
[TBL] [Abstract][Full Text] [Related]
17. Reclassification of urinary cytology regarding The Paris System for Reporting Urinary Cytology with cytohistological correlation demonstrates high sensitivity for high-grade urothelial carcinoma.
Anbardar MH; Monjazeb R
Diagn Cytopathol; 2020 May; 48(5):446-452. PubMed ID: 31976626
[TBL] [Abstract][Full Text] [Related]
18. Keratin 17 Is a Novel Cytologic Biomarker for Urothelial Carcinoma Diagnosis.
Babu S; Kim NW; Wu M; Chan I; Escobar-Hoyos LF; Shroyer KR
Am J Clin Pathol; 2021 Oct; 156(5):926-933. PubMed ID: 34086841
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of urinary molecular markers in bladder cancer.
Eissa S; Swellam M; el-Mosallamy H; Mourad MS; Hamdy NΜ; Kamel K; Zaglol AS; Khafagy MM; el-Ahmady O
Anticancer Res; 2003; 23(5b):4347-55. PubMed ID: 14666650
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.
Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA
Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
